Clinical Trial Update: A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea [Phase 3]

View source ↗

Summary

A Phase 3 study of brodalumab (KHK4827) for moderate to severe plaque psoriasis in Korea has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: Kyowa Kirin Korea Co., Ltd. | Conditions: Moderate to Severe Plaque Psoriasis | Phase 3 | Status: COMPLETED